{
    "nctId": "NCT03892655",
    "briefTitle": "Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer",
    "officialTitle": "A Multicenter, Prospective, Real World, National Study to Assess the Efficacy and Safety of Adjuvant Biosimilar Tratuzumab (Zedora) Treatment in Patients With Localized Her2 Positive Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 170,
    "primaryOutcomeMeasure": "Efficacy endpoints: Invasive disease relapse-free survival rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients aged 18 years and over\n* diagnosis of early stage I to III breast cancer confirmed by histopathology test according to local guidelines.\n* human epidermal growth factor receptor 2 (HER2)-positive tumor by immunohistochemistry or FISH (Fluorescence In Situ Hybridization), as per the 2018 ASCO assessment guideline \\[J Clin Oncol 36:2105, 2018\\].\n* use of at least one dose of biosimilar trastuzumab (Zedora) as adjuvant therapy, regardless of previous neoadjuvant trastuzumab or Zedora use or the type of chemotherapy combined with the antibody.\n* Signing of the informed consent form (ICF).\n\nExclusion Criteria:\n\n* use of biosimilar trastuzumab (Zedora) differently from the provisions in the label.\n* patients enrolled in and followed up by Programa Vida Plena \\[Full Life Program\\].",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}